Large Cohort Blood Proteomics Service

Biomarkers are essential to precision medicine, significantly influencing early disease diagnosis, prognosis assessment, and personalized treatment strategies. However, many existing biomarkers exhibit inadequate specificity, and the transition of new biomarkers into clinical practice remains slow. Blood, as a vital biological sample, is extensively utilized in biomarker research, particularly in early disease diagnosis and prognosis guidance, underscoring its substantial research potential.

 

The intricate composition of blood presents considerable challenges for biomarker detection and analysis. Protein concentrations in blood can vary dramatically, even reaching levels as high as 10^12, making sensitivity and specificity critical for accurate analyses. Rapid technological advancements have significantly enhanced the quantitative depth and throughput of omics technologies, such as blood proteomics, establishing them as indispensable tools in biomarker research. Additionally, the exploration of abundant glycosylated proteins, exosomes, and small metabolites in blood is gaining traction, further expanding the research potential for quantitative blood omics analysis.

 

Large cohort blood proteomics employs high-throughput mass spectrometry (MS) along with advanced labeling techniques to enable efficient and accurate quantification of thousands of proteins within complex biological samples. MtoZ Biolabs specializes in the analysis of blood samples, offering comprehensive Large Cohort Blood Proteomics Service. This program facilitates high-throughput quantitative analysis of proteins, glycoproteins, exosomal proteins, and metabolites in blood, significantly advancing biomarker research and its clinical applications.

 

Analysis Workflow

 



Niu, L. et al. Nat Med. 2022.

 

Service Advantages

1. High throughput and sensitivity

Capable of simultaneously analyzing thousands of proteins, thereby enhancing the efficiency of biomarker discovery.

 

2. In-depth quantitative analysis

Recent technological advancements have greatly improved quantitative depth, making it suitable for low-abundance protein detection.

 

3. Versatile adaptability

Capable of processing various sample types to meet diverse research needs.

 

Sample Submission Requirements

Blood samples should be no less than 1 mL, and serum/plasma samples should be at least 200 μL. For more detailed requirements regarding sample submission, please contact our technical support.

 

Applications

• Early Disease Diagnosis
• Disease Progress Monitoring
• Personalized Medicine
• Biomarker Development

 

FAQ

Q1: What are the research applications for blood cells, plasma, platelets, and PBMCs?

The components of blood are complex. Blood cells, which include various types, are suitable for single-cell studies and are more appropriately analyzed using single-cell sequencing, although advancements are needed for single-cell proteomics. Platelets, being anucleated with limited genomic content, are less ideal for sequencing and are better suited for investigations related to proteins and metabolites. Plasma contains a wealth of proteins, making it suitable for proteomic studies focused on biomarker discovery and disease diagnosis. PBMCs, which include lymphocytes and monocytes, are appropriate for studies involving gene and protein expression.

 

Q2: How can batch effects be minimized?

To minimize batch effects, we employ random sampling techniques during sample preparation and collection to ensure diverse representation across groups based on age and sex. Each batch processed in mass spectrometry includes both biological and technical replicates. Data collection is performed using multiple instruments simultaneously, and algorithms are applied to mitigate batch effects. The final dataset shows no significant batch effects, allowing for reliable subsequent analyses.